Journal
KIDNEY INTERNATIONAL REPORTS
Volume 2, Issue 1, Pages 108-123Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ekir.2016.09.055
Keywords
AKI; chemotherapy; hypokalemia; hyponatremia; nephrotoxicity; onconephrology; renal failure; targeted therapy
Categories
Ask authors/readers for more resources
Novel targeted anti-cancer therapies have resulted in improvement in patient survival compared to standard chemotherapy. Renal toxicities of targeted agents are increasingly being recognized. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here we review the adverse renal effects associated with a selection of currently approved targeted cancer therapies, directed to EGFR, HER2, BRAF, MEK, ALK, PD1/PDL1, CTLA-4, and novel agents targeted to VEGF/R and TKIs. In summary, electrolyte disorders, renal impairment and hypertension are the most commonly reported events. Of the novel targeted agents, ipilumumab and cetuximab have the most nephrotoxic events reported. The early diagnosis and prompt recognition of these renal adverse events are essential for the general nephrologist taking care of these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available